Skip to content
Preprint · CC-BY via OpenAlex

Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency

Lawrence A. Donehower

Aging · 2012 · ▲ 26 citations

Abstract

Comment on: 1. Komarova et al. mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012; 4:10 2. Comas et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging.2012; 4;10.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.18632/aging.100494
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Donehower, L.A. (2012). Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. <em>Aging</em>. https://doi.org/10.18632/aging.100494
Vancouver
Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging. 2012. doi:10.18632/aging.100494.
BibTeX
@unpublished{lawrence2012Rapamy, title = {Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency}, author = {Lawrence A. Donehower}, journal = {Aging}, year = {2012}, doi = {10.18632/aging.100494}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings